England's measles jab rate is rising on average. In the poorest areas it is falling.

One number went up. The number underneath it went down.

England's coverage of the second dose of the MMR vaccine, measured in children turning five, rose 0.3 percentage points to 84.1% in the quarter to March 2026. That is the third consecutive quarterly rise, from a low of 83.2% in the quarter to June 2025.¹² On its own, the national average reads as a slow recovery.

The same release splits that average by deprivation for the first time, using the 2025 Index of Multiple Deprivation.¹ Split in two, the recovery disappears. In the 30 least deprived upper-tier councils, second-dose coverage rose 0.5 points to 88.0%. In the 30 most deprived, it fell 0.9 points to 77.4%. The two groups moved in opposite directions in the same quarter, and the gap between them widened by 1.4 points, to 10.6.¹

Of the four gaps UKHSA publishes, measles has the widest

The same release reports the most-versus-least-deprived gap for four childhood vaccine measures. They are not equally wide. The 6-in-1 vaccine given at 12 months shows a 6.2-point gap; first-dose MMR at 24 months, 7.9 points; the 6-in-1 measured at five years, 4.9 points. Second-dose MMR at five is the widest at 10.6 — more than double the narrowest.¹

UKHSA states that for both MMR measures the difference between the groups "has been increasing in the last 6 years", with the least deprived group broadly stable and the most deprived declining.¹ This desk's reading is that the pattern is not a general vaccine-hesitancy effect: the 6-in-1 gap at five years is the narrowest of the four, and the same children are eligible for both. What separates MMR2 is that it is a later, opt-in-again appointment at three years and four months, after the intensive first-year schedule has ended — but no study in the release isolates that as the cause, and this remains an inference, not a finding.

England has not recorded a measles-free week in more than two years

In January 2026 the World Health Organization confirmed that the UK had lost its measles elimination status, alongside Armenia, Austria, Azerbaijan, Spain and Uzbekistan.⁴ The decision is easy to misread as a verdict on how many people caught measles. It is not. WHO defines elimination as the absence of endemic transmission for 12 months or more in the presence of good surveillance, and treats it as re-established when the same viral strain circulates continuously for 12 months or more.⁴⁵ The criterion is duration, not height.

That distinction matters because it inverts the obvious metric. England recorded 2,911 laboratory-confirmed cases in 2024, the highest annual total since 2012, and 959 in 2025.³ Between 1 January and 6 July 2026 it recorded 883.⁶ By case count, 2026 is running at around 30% of 2024. By the criterion that actually governs elimination, none of that is the point: across the 119 weeks from January 2024 to early April 2026, there is not a single week in which England reported zero confirmed cases. The quietest week on record in that span — the week beginning 18 August 2025 — had four.⁶

Elimination is a claim about the floor, not the ceiling. A country can have a bad year and keep its status if transmission is broken; a country with a quiet year loses it if transmission never stops. That is the link back to Exhibit 01. Herd protection against measles is local, not national — which is why the WHO sets its 95% target as a threshold to be met, not an average to be approached.⁵ A national figure of 84.1% and a most-deprived figure of 77.4% describe the same country; only one of them describes where the virus keeps finding a way through.

Two things the coverage figure does not tell you

It is old. Coverage of the second MMR dose measured in five-year-olds this quarter reflects vaccinations that should have been delivered between May and July 2024; the children counted were born in the quarter to March 2021.¹ The most recent coverage number available in July 2026 is a reading on appointments due roughly two years ago. It cannot yet show the effect of the catch-up campaign NHS England launched in July 2026, which is contacting around a million families.⁷

Its benchmark moves. UKHSA reports current coverage against the peak of "the last 10 years" — a rolling window. In the releases for the first three quarters of 2025 to 2026, MMR2 was reported against a peak of 88.2%, recorded in the quarter to March 2016. In the latest release the stated peak is 87.8%, from the quarter to December 2016.¹² The gap to peak duly narrowed, from 5.0 points to 3.7. But 0.4 points of that 1.3-point improvement is the window rolling forward and dropping the old high, not coverage improving; only 0.9 points is a real gain. It is a small artifact, and a useful reminder that "closest to the peak in years" is a claim about the window as much as the data.

Read more

• The unregistered children. UKHSA reports London children not registered with a GP separately, and the numbers are far lower again — 7.5% second-dose coverage. The release cautions these figures are highly uncertain and likely to understate true coverage, so we have kept them out of the analysis above.
• The MMRV switch. From January 2026 England replaced MMR with a four-in-one MMRV vaccine adding chickenpox, at 12 and 18 months. Its effect on uptake will not appear in five-year-old coverage for years.
• The European picture. The UK was one of six countries to lose elimination status in January 2026; WHO's regional commission found the number of countries with endemic transmission rose from 12 to 19. We have held this piece to England.